The tussle had centred on the development of mRNA jab technology, which was at the forefront of the fight against Covid-19.

Shares of GSK fell to below $30 around the time of the demerger, but have since recovered to about $36. The 20% gain over 34 ...

UK-based big pharma GlaxoSmithKline (GSK) has released its Q2 2025 results, which highlight the varying successes of its ...

GSK will partner with Hengrui Pharma to develop up to 12 treatments for indications in respiratory, immunology and ...

GlaxoSmithKline (GSK) is currently conducting a Phase 4 clinical study titled ‘A Phase 4, Multicenter, Prospective, Open-Label Study Describing the Efficacy and Safety of Belimumab Administered ...

In a report released today, Justin Smith from Bernstein maintained a Buy rating on GlaxoSmithKline, with a price target of £21.70. The company’s shares closed today at p1,373.00. Take advantage of ...

Indian drugmaker GlaxoSmithKline Pharma reported its first quarterly revenue decline in more than two years on Friday, ...

GlaxoSmithKline (GSK) has agreed to acquire Affinivax for up to $3.3 billion, in a deal designed to strengthen the buyer’s vaccine portfolio with jabs based on Affinivax’s technology.

Shares of GlaxoSmithKline GSK declined 2.4% on Jan 19 after Unilever UL expressed its unwillingness to raise its bid of £50 billion (approximately $68 billion) for Glaxo’s consumer healthcare ...

GlaxoSmithKline GSK announced an agreement to acquire joint development and commercialization rights to iTeos Therapeutics’ ITOS early-stage cancer candidate, EOS-448, an anti-TIGIT monoclonal ...

GlaxoSmithKline PLC GSK -3.16% has agreed to buy Sierra Oncology Inc. for $1.9 billion, in a deal that will boost the British pharmaceutical giant’s cancer drug pipeline. The deal centers on a ...